2024-06-10 LIDR Meeting Notes

Name	Organization

Name	Organization
Hung Luu	Children’s
Riki Merrick	Vernetzt, APHL
Andrea Pitkus	UW
Pam Banning	3M - Solventum
Xavier Gansel	Biomerieux
Amy McCormick	Epic
Dan Rutz	Epic
Rob Rae	CAP
Rob Hausam	Hausam Consulting
Sandy Jones	CDC
Stan Huff	Graphite
Ed Heierman	Abbott / IICC
Andrew Quinn
Laurent Lardin	Biomerieux
Anthony Killeen	UMN
Craig Collom
Marti Velezis	Sonrisa / FDA
Walter Sujansky	FDA
Susan Downer	JMC
Ralf Herzog	Roche
Cornelia Felder	Roche
Daniel Golson	JMC
Andrea Prada	JMC
Maria Sagat	CAP
Raja Cholan	FDA
Russ Ott	FDA
Akila Namasivayam	FDA
Desiree Mustaquim	CDC
Christina Gallegos	APHL
John Spinosa	Lantana

Agenda and Notes

Topic	Notes

Topic	Notes
Reviewing minutes from the last call - Action Item Follow up	Pull out the definitions from LIVD for test kit and equipment and put here: SHIELD Glossary Review operational definition of “equivalence” Outreach to Dr. DeBaca Hung will check for more info and maybe see, if she could participate in SHIELD Keep updating the googlesheet: Potassium LIVD data Shared Reportable Conditions LIVD google sheet for crowdsourcing with CSTE - added sign up sheet for PHAs to specific conditions and see how that develops Have LIVD File Repository Requirements Have draft budget (for setting up a web-based database and yearly maintenance): https://aphlinformatics.atlassian.net/wiki/download/attachments/915407143/LIDR - Budget.xlsx?api=v2 Review LIDR Use Cases and sign up to lead one of these - prioritize these use cases, so that we can finalize the requirements for the first phase of LIDR Define next steps to migrate existing LIVD files into FHIR LIVD catalog format and find a FHIR server to host Marti can share the LIDR categorical data to instance data mapping for each element for June 3, 2024
Call Schedule	send OOO via chat or email
LIDR Elements Discussion	Specimen Information should include 3 elements to be completely defined Specimen Type - Specimen SNOMED Hierarchy Collection Method - SNOMED Procedure Hierarchy Specimen Source Discussion around Specimen Source Only include Anatomic Site Allow use of SSNOMED Substance Hierarchy Should be a required element when appropriate May be out of scope for inclusion in LIDR as it would be difficult to anticipate all the possible anatomic sites a specimen may be collected from (e.g., mpox with multiple possible lesion sites or wound culture) Where Specimen Source site is essential such as included in 510(k) approval the information could be incorporated into the Specimen Type (e.g., nasopharyngeal swab, vaginal swab) Should the white paper address Specimen Source if it is a recommended data element but is not included in LIDR
	Discussion about inclusion of reference range: vendor provided reference range is the only thing that could be in LIDR - supports labs setting up the test - for instance data, will have to use the refernece range provided with the result Sidebar: Sequoia Lab Tiger team (TEFCA members recommendation around lab use cases) - we want to make sure their IGs supports real world evidence and provide them with the solutions SHIELD has already come up
ACTION ITEMS	Please see the action items at top of this page - Next deliverable is White paper draft by end of this month
Next call	Monday 6/17/2024 9 - 10 AM ET
Adjourned